Full-Time

Associate Director

Strategic Partnerships

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Risk Management

You match the following Moderna's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree in a relevant discipline.
  • Minimum of 10+ years of experience in the pharmaceutical or biotech industry, with at least 6 years in strategic partnering, alliance, or vendor management.
  • Demonstrated ability to govern and manage external partnerships successfully.
  • Strong business acumen, including project management, meeting facilitation, and analytical skills.
  • Experience in establishing and monitoring metrics aligned with KPIs, KQIs, and KRIs.
Responsibilities
  • Lead and deliver partnership value and continuous improvement within a strategic global partnership.
  • Oversee and maintain the partnership governance model to ensure optimal performance.
  • Facilitate change management initiatives with internal stakeholders and partners to improve processes and drive efficiencies.
  • Plan, implement, and monitor partnership activities in collaboration with internal functional leadership and teams.
  • Drive resolution of conflicts and escalations at all levels to maintain effective partnership relations.
  • Manage performance and quality metrics through scorecard evaluation and analysis.
  • Identify opportunities for optimization and innovation through evaluation of partner capabilities.
  • Build and maintain strong relationships with internal and external stakeholders to align objectives and foster collaboration.
  • Communicate Moderna’s goals and objectives, ensuring alignment with partner strategies.
  • Monitor partnership health through surveys and feedback mechanisms, implementing improvements as needed.
  • Identify and execute value-add projects to optimize partnership delivery.
  • Implement a tailored governance model and communication plan for each partnership.
  • Lead governance interactions and committees, including agenda preparation, prioritizing discussions, and tracking action items.
  • Provide regular updates to Moderna leadership and key stakeholders on partnership progress.
  • Support contract negotiations and renegotiations, collaborating with Procurement and Clinical Outsourcing teams.
  • Maintain a partnership-level risk log and oversee action and decision logs for governance.
  • Influence stakeholders to deliver partnership objectives, including prioritizations, budgeting, and strategic planning.
  • Integrate and implement best practices from other Moderna partnerships to drive continuous improvement.
  • Actively promote a partnering mindset within the Development organization.
Desired Qualifications
  • Advanced degree preferred.
  • Experience creating and implementing vendor management processes and functional excellence initiatives.
  • Exceptional written and oral communication skills.
  • Proven ability to lead and manage meetings effectively.
  • Strong interpersonal skills to influence and inspire across functions and levels.
  • Strategic and innovative thinking with a solutions-oriented approach.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial molecule that provides instructions for cells to produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially transform how drugs are discovered, developed, and manufactured. Unlike traditional pharmaceuticals, which often rely on proteins or small molecules, Moderna's mRNA-based therapies aim to instruct the body to produce its own therapeutic proteins. This unique method sets Moderna apart from competitors, as it opens up new possibilities for treating diseases and improving patient outcomes. The company's goal is to harness the power of mRNA to create effective treatments that can significantly enhance the quality of life for patients.

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$6.5B

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna secured a $590 million contract for bird flu vaccine development.
  • The company is expanding its mRNA applications to rare diseases and cancer.
  • Moderna's cost reduction efforts aim to save nearly $1 billion by 2025.

What critics are saying

  • Increased competition from BioNTech and Pfizer may impact Moderna's market share.
  • Potential regulatory delays could affect Moderna's growth and revenue targets.
  • Fluctuating COVID-19 vaccine demand creates uncertainty in Moderna's sales forecasts.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has a strong late-stage pipeline with multiple product approvals anticipated.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

4%
PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S

The Scotsman
Feb 13th, 2025
Scotland's Life Sciences Conference & Awards 2025: Uniting industry leaders to shape the future

Scotland's thriving life sciences sector, a key driver of innovation and economic growth, is set to take centre stage in 2025 with the launch of Scotland's Life Sciences Conference, sponsored by Moderna.

PharmiWeb
Jan 29th, 2025
Moderna To Report Fourth Quarter And Full Year 2024 Financial Results On Friday, February 14, 2025

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines

PharmiWeb
Jan 24th, 2025
Moderna Awarded Tender For The Supply Of Its Mrna Covid-19 Vaccine In The European Union

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formatsCAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years."This agreement presents an opportunity for Moderna to support and strengthen national COVID-19 vaccination campaigns across participating countries," said Chantal Friebertshäuser, Senior Vice President, General Manager - Europe & Middle-East, Moderna. "Diversity of supply and availability of vaccine formats such as pre-filled syringes are vital to help increase vaccination rates and enhance vaccination campaign efficiency, ultimately strengthening health security."Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone

Managed Healthcare Executive
Jan 22nd, 2025
Moderna Awarded $590 Million for Bird Flu Vaccine Development

The development of avian influenza vaccines is the main priority amid rising cases in the United States.